MYH9

Across TCGA pan-cancer cohorts, MYH9 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated MYH9 data layer compared with 12 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher MYH9 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MYH9 expression acts as an unfavorable survival marker, although some lineages such as SCLC and ESCA show a favorable association.

MESO, ACC, and SCLC are the cancer types where MYH9 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.397	0.683	<.001	111	view →
ACC	DFS	Median	All	0.233	0.647	<.001	78	view →
SCLC	DFS	Median	All	0.763	0.478	<.001	63	view →
LGG	OS	Median	All	0.352	0.556	<.001	54	view →
KIRP	DFS	Quartile	All	0.843	0.971	.003	38	view →
ESCA	OS	Median	III,IV	0.713	0.443	.008	30	view →
KIRC	DFS	Tertile	All	0.767	0.477	.001	28	view →
UCEC	DFS	Median	III,IV	0.862	0.722	.003	26	view →
UCS	DFS	Tertile	IV	0.956	0.380	.024	24	view →
LUSC	DFS	Median	III,IV	0.339	0.968	<.001	24	view →
HNSC	OS	Quartile	All	0.254	0.659	.002	21	view →
OV	DFS	Tertile	IV	0.347	0.575	.004	20	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

MYH9–MESO (OS)

Open the MESO breakdown →